⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12269116 | 0.92 | TDP1 (0.40) | — | |
| SCHEMBL12601084 | 0.82 | — | — | |
| SCHEMBL15314300 | 0.82 | — | — | |
| SCHEMBL13468451 | 0.82 | — | — | |
| SCHEMBL19352395 | 0.82 | — | — | |
| SCHEMBL19442942 | 0.82 | — | — | |
| SCHEMBL14468461 | 0.81 | LMNA (0.41) | — | |
| SCHEMBL27989508 | 0.81 | LMNA (0.41) | — | |
| SCHEMBL22652150 | 0.80 | TDP1 (0.40) | — | |
| SCHEMBL10561000 | 0.80 | TDP1 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10738056-B2 | Pyrazolopyrimidinone compounds and uses thereof | ADURO BIOTECH INC. (US) | 2020-08-11 | — | — | US | disclosed |
| EP-3317286-B1 | CYCLIZED SULFAMOYLARYLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2019-09-11 | — | — | EP | disclosed |
| US-20190119285-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF | CHINOOK THERAPEUTICS, INC. | 2019-04-25 | — | — | US | disclosed |
| US-20110212940-A1 | S1P Receptor Modulating Compounds and Use Thereof | EPIX PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-7919519-B2 | 1-(4-(5-Phenylbenzofuran-2-yl)benzyl)azetidine-3-carboxylic acids; anticarcinogenic, antiinflammatory, antiarthritic, antidiabetic agents; transplant rejection, autoimmune diseases, lupus, multiple sclerosis, psoriasis, inflammatory bowel disease, Chron's disease | EPIX PHARMACEUTICALS INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-20110059945-A1 | S1P Receptor Modulating Compounds and Use Thereof | EPIX PHARMACEUTICALS, INC. (US) | 2011-03-10 | — | — | US | disclosed |
| EP-1812381-B1 | ETHYLENICALLY UNSATURATED GROUP-CONTAINING ISOCYANATE COMPOUND AND PROCESS FOR PRODUCING THE SAME, AND REACTIVE MONOMER, REACTIVE (METH)ACRYLATE POLYMER AND ITS USE | SHOWA DENKO KK (JP) | 2011-02-16 | — | — | EP | disclosed |
| US-7855193-B2 | S1P receptor modulating compounds and use thereof | EPIX PHARMACEUTICALS, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| US-20100317649-A1 | S1P Receptor Modulating Compounds and Use Thereof | EPIX PHARMACEUTICALS, INC. (US) | 2010-12-16 | — | — | US | disclosed |
| US-7790707-B2 | S1P receptor modulating compounds and use thereof | EPIX PHARMACEUTICALS INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7579066-B2 | Ethylenically unsaturated group-containing isocyanate compound and process for producing the same, and reactive monomer, reactive (meth) acrylate polymer and its use | SHOWA DENKO K.K. (JP) | 2009-08-25 | — | — | US | disclosed |
| US-20080132597-A1 | Ethylenically Unsaturated Group-Containing Isocyanate Compound and Process for Producing the Same, and Reactive Monomer, Reactive (Meth) Acrylate Polymer and its Use | RESONAC CORPORATION (JP) | 2008-06-05 | — | — | US | disclosed |
| US-20080064677-A9 | S1P receptor modulating compounds and use thereof | PREDIX PHARMACEUTICAL HOLDINGS | 2008-03-13 | — | — | US | disclosed |
| US-20080027036-A1 | S1P receptor modulating compounds and use thereof | EPIX DELAWARE, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080015177-A1 | S1P receptor modulating compounds and use thereof | AMGEN INC. | 2008-01-17 | — | — | US | disclosed |
| US-20070173487-A1 | S1P receptor modulating compounds and use thereof | PREDIX PHARMACEUTICAL HOLDINGS | 2007-07-26 | — | — | US | disclosed |